{
  "actions": [
    {
      "acted_at": "2023-09-29",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2023-09-29",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    },
    {
      "acted_at": "2023-10-06",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr5850-118",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "118",
  "cosponsors": [
    {
      "bioguide_id": "M001194",
      "district": "2",
      "name": "Moolenaar, John R.",
      "original_cosponsor": true,
      "sponsored_at": "2023-09-29",
      "state": "MI",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2023-09-29",
  "number": "5850",
  "official_title": "To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.",
  "popular_title": null,
  "related_bills": [],
  "short_title": null,
  "sponsor": {
    "bioguide_id": "M000871",
    "district": "1",
    "name": "Mann, Tracey",
    "state": "KS",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2023-09-29",
  "subjects": [
    "Abortion",
    "Drug safety, medical device, and laboratory regulation",
    "Health",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": null,
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.",
      "type": "official"
    }
  ],
  "updated_at": "2024-07-24T15:20:15Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/118/hr/BILLSTATUS-118hr5850.xml"
}